COVID-19

Convalescent plasma trial shows no benefit

Subjects

Passive immunization with convalescent plasma (CP) is being evaluated as a treatment for COVID-19. A multicentre, open-label, randomized, controlled trial was conducted in India in which patients received either best standard of care (BSC) (n = 229) or BSC coupled with two 200 ml doses of CP (n = 235). Despite lower viral RNA measured in patients who received CP, there was no difference in 28-day mortality or progression to severe disease between treatment arms. Importantly, 83% of study participants showed detectable neutralizing antibodies (nAbs) at enrolment and nAb titres did not change after treatment. Although this trial failed to demonstrate therapeutic efficacy, future investigations using CP pre-screened for higher nAb titres or treating nAb-naive patients may be warranted.

References

Original article

  1. Agarwal, A. et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). Preprint at medRxiv https://doi.org/10.1101/2020.09.03.20187252 (2020)

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Matthew Brown.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Brown, M. Convalescent plasma trial shows no benefit. Nat Rev Immunol 20, 649 (2020). https://doi.org/10.1038/s41577-020-00461-3

Download citation

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing